GRI Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$4.77next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly11MTarget: Maintain sufficient capital to initiate and complete Phase 2b clinical trials of GRI-0621
GRI-0621 Phase 2b Clinical Trial Initiation AnnuallyTarget: Initiate Phase 2b clinical trial evaluating GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF)
GRI-0803 IND-Enabling Activities AnnuallyTarget: Complete IND-enabling studies to advance GRI-0803 toward clinical development in autoimmune indications
Watch Items
- Capital Deficit and Going Concern RiskTrigger: Cash runway falling below 6 months of operating expenses without securing additional financing or strategic partnershipsAction: Execute further capital raises under the amended At-The-Market (ATM) stock offering program or secure non-dilutive strategic partnerships
- Nasdaq Listing ComplianceTrigger: Stock price falling below the $1.00 minimum bid price requirement for 30 consecutive business days post-reverse splitAction: Evaluate further corporate actions, including potential share consolidations or capital restructuring, to maintain listing
Research as of 20 Jun 2026